Option chain shows key data for Innate Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innate Pharma.

Innate Pharma (NASDAQ:IPHA) Stock, Option Chain

INNATE PHARMA SA-SPONS ADR

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Recent Gains

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

AKTS

ATCH

BTCT

EWTX

FUFU

KPTI

KTOS

LAES

PRTC

RDZN

SGMT

SIDU

SMCI

STEC

TNXP

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

The Boeing Company (BA)

Earnings

CLEU

KARO

NRIX

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Press Releases

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma Reports Full Year 2024 Financial Results and Business Update

PARIS:IPH

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

INmune Bio

Inventiva S.A. - American Depository Shares

Inventiva

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kodiak Sciences

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

HC Wainwright & Co.

SVB Leerink

Citigroup

Comments

Innate Pharma

Innate Pharma (IPHA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga